BioMedWire Stocks

Tech Giants Unveil AI Tools to Support e-Commerce, Healthcare and Video Production

In the last fortnight, leading technology companies have unveiled a number of artificial intelligence tools which could have a huge impact on the e-commerce, healthcare and video production fields.

Adobe released its Firefly Video production tool. The model allows corporate users to reduce the costs associated with video production and also streamline the entire process. With the AI tools from Adobe, users can provide text prompts in any of at least 100 supported languages and have custom videos generated. Experts clarify that the efficiency-boosting attributes of these video creation tools shouldn’t be seen as a replacement for humans. Instead, the tools complement the creativity of a company’s staff.

OpenAI and other platforms have also brought to market AI tools aimed at fostering real-time cooperation during the content-creation process of players in the e-commerce industry. Tools like Canva from OpenAI now allow users to quickly come up with product descriptions in different languages in ways that leverage contextual differences while enabling humans to interact with AI seamlessly. These tools can enable business communication to be consistent, boost productivity and save employee time that can be deployed in other higher-order creative tasks.

Microsoft wants to transform the way different tasks are performed within the healthcare sector. Of specific interest are diagnostic accuracy and healthcare system administration. Through its cloud-based solutions, Microsoft aims to boost patients’ outcomes, automate paperwork and also improve the integration of data. The range of tools that this tech titan offers includes advanced algorithms to analyze medical data and detect any hidden patterns, AI-backed chatbots which take care of routine inquiries from consumers of healthcare services, among others. These tools can take most repetitive tasks away from healthcare professionals and allow them to concentrate on patient care.

Not to be outdone, Google is also placing its mark on healthcare AI through its different tools that have raised the stakes for tailored technology solutions. The Tx-LLM AI tool from Google DeepMind is an industry-specific AI model aimed at reshaping pharmaceutical research while also accelerating the drug discovery process. These specialized AI tools have already proven to be superior to the general-purpose models that preceded them, and the tools can potentially reduce the time and other resources needed to conduct a drug development program.

Different industries and sectors are embracing tailored artificial intelligence, and those tools have the potential to help entities optimize their specific workflows while also easing the navigation of the often complex regulations governing those industries.

e-Commerce service providers like NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) with interests in the healthcare space now have an increasing array of AI tools that they can deploy to support the quest to attain their business objectives.

NOTE TO INVESTORS: The latest news and updates relating to NextPlat Corp. (NASDAQ: NXPL, NXPLW) are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected…

20 hours ago

Adageis Offering Comprehensive Healthcare AI Tools to Support Profitable Shift to Value-Based Care

Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive…

5 days ago

Scientists ID Bacteria That Could Be Behind Multiple Sclerosis Development

A new study focusing on twins has found that individuals with a larger presence of…

5 days ago

How Stem Cells Help in Blood Cancer Treatment

Stem cells are the “master cells” within the body because they can grow into any…

6 days ago

UnitedHealth Records Lower Revenue as Medical Advantage Use Grows

UnitedHealth Group, the largest health insurance firm in the U.S., has reduced its revenue forecast…

1 week ago

Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery

Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform AVERSA(TM) Fentanyl targets $80M–$200M…

1 week ago